Literature DB >> 21693121

Central PGE2 exhibits anxiolytic-like activity via EP1 and EP4 receptors in a manner dependent on serotonin 5-HT1A, dopamine D1 and GABAA receptors.

Chihiro Suzuki1, Chihiro Miyamoto, Tomoyuki Furuyashiki, Shuh Narumiya, Kousaku Ohinata.   

Abstract

We found that centrally administered prostaglandin (PG) E(2) exhibited anxiolytic-like activity in the elevated plus-maze and open field test in mice. Agonists selective for EP(1) and EP(4) receptors, among four receptor subtypes for PGE(2), mimicked the anxiolytic-like activity of PGE(2). The anxiolytic-like activity of PGE(2) was blocked by an EP(1) or EP(4) antagonist, as well as in EP(4) but not EP(1) knockout mice. Central activation of either EP(1) or EP(4) receptors resulted in anxiolytic-like activity. The PGE(2)-induced anxiolytic-like activity was inhibited by antagonists for serotonin 5-HT(1A), dopamine D(1) and GABA(A) receptors. Taken together, PGE(2) exhibits anxiolytic-like activity via EP(1) and EP(4) receptors, with downstream involvement of 5-HT(1A), D(1) and GABA(A) receptor systems.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21693121     DOI: 10.1016/j.febslet.2011.06.004

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 2.  Consequences of essential fatty acids.

Authors:  Bill Lands
Journal:  Nutrients       Date:  2012-09-24       Impact factor: 5.717

Review 3.  E-type prostanoid receptor 4 (EP4) in disease and therapy.

Authors:  Viktoria Konya; Gunther Marsche; Rufina Schuligoi; Akos Heinemann
Journal:  Pharmacol Ther       Date:  2013-03-21       Impact factor: 12.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.